Overview

Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events

Status:
Active, not recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate optimal duration of antiplatelet therapy after Bioresorbable Vascular Scaffold implantation to reduce late coronary arterial thrombotic events.

Phase:

Phase 4

Details

Lead Sponsor:

Seung-Jung Park

Collaborator:

CardioVascular Research Foundation, Korea

Treatments:

Aspirin
Clopidogrel
Ticlopidine